Robert S. Lowe

48 papers receiving 1.6k citations

Peers

Robert S. Lowe
Comparison fields: 5 of 105
  • Virology 99
  • Epidemiology 545
  • Cancer Research 209
  • Surgery 599
  • Immunology 228
Replace John E. Sagartz with:
John E. Sagartz United States
Heather M. Smith United Kingdom
James Tamura United States
Yong Lin China
Carlos Penha‐Gonçalves Portugal
Tahar van der Straaten Netherlands
Kong‐Nan Zhao Australia
Larry S. Schlesinger United States
Robert S. Lowe relative to John E. Sagartz United States John E. Sagartz's profile →
Citations per field
00.5×6.4×
John E. Sagartz · 1×
Citations per year

Countries citing papers authored by Robert S. Lowe

Since Specialization
Citations

This map shows the geographic impact of Robert S. Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Lowe more than expected).

Fields of papers citing papers by Robert S. Lowe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Lowe. The network helps show where Robert S. Lowe may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert S. Lowe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert S. Lowe Line = papers co-authored together Robert S. Lowe links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2012204
2 1986125
3 1997105
4 199990
5 200575
6 198770
7
Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.
200862
8 200960
9 201158
10 197552
11 199050
12 201546
13 198544
14 200043
15 201340
16 198037
17 198937
18 200635
19 200234
20 197933

About Robert S. Lowe

Robert S. Lowe is a scholar working on Cancer Research, Virology, Surgery, Endocrinology and Economics and Econometrics, having authored 49 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (18 papers), Pharmaceutical Economics and Policy (10 papers), Virus-based gene therapy research (8 papers), Cancer, Lipids, and Metabolism (7 papers), Herpesvirus Infections and Treatments (6 papers), Plant Pathogens and Resistance (6 papers), Cervical Cancer and HPV Research (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). The work is most often cited by research in Virology (99 citations), Epidemiology (545 citations), Cancer Research (209 citations), Surgery (599 citations) and Immunology (228 citations). Robert S. Lowe has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Paul M. Keller, Andrew M. Tershakovec, M. C. M. Pérombelon, Ronald W. Ellis, J. G. HARRISON, Andrew J. Davison, Jianxin Lin, Arvind Shah, Mary E. Hanson and Peter P. Tóth. Their work appears in journals such as Plant Pathology, Journal of Virology, The American Journal of Cardiology, Potato Research and Atherosclerosis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026